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EDITORIAL

Set Theory: Nephrology X Urology

E

ach new patient encounter for me engenders 2 proclamations. The ﬁrst is the formal introduction of name,
and the second is to deﬁne who I am, a nephrologist,
and who I am not, a urologist. The Guest Editors, Dr Hoenig, an adult nephrologist, and Dr Neu, a pediatric
nephrologist, have placed us at the crossroads of
Nephrology and Urology in this issue of Advances in
Chronic Kidney Disease. Their intent and that of the invited
authors of this review is for nephrologists to more fully
acknowledge and comprehend what urologists do
because some urological disorders affect the practice of
Nephrology. It is important that nephrologists are knowledgeably prepared when urological problems that intersect with Nephrology come our way.
By virtue of the titular term “crossroads,” the Guest Editors denote that Nephrology intersects the urological
discipline at 1 or more places, that Nephrology and Urology represent a small community at such intersections, or
that both parties are at a crucial point, particularly where
a decision must be made. However, the “or” is not an
exclusive one, and depending on the prevailing circumstances, any of the 3 denotations may apply in a given
clinical scenario. Several examples of the crossroads of
Nephrology and Urology follow.
With improved urological care of infants and children,
the adult nephrologist must now appreciate congenital
anomalies of the kidney and urinary tract (CAKUT)
because these individuals will invariably enter one’s clinical practice. CAKUT is an important and prevalent group
of disorders. Among these are congenital obstructive uropathy, primary megaureter, ectopic ureter, duplicated
ureter, fusion and ectopic abnormalities, and multicystic
dysplasia and cystic disorders of children. Using standardized sonographic evaluation of 30,940 infants and fetuses, nearly 7% were considered major malformations
and 35.8% mild morphogenetic errors. CAKUT constituted approximately one-quarter of identiﬁable, prenatal
anomalies. Furthermore, CAKUT contributes to the development of ESRD in children in 30% to 50% of cases.1
Spina biﬁda patients may develop CKD. The combination of a dysfunctional bladder outlet is often compounded by secondary vesicoureteral reﬂux.2 Repeated
urinary tract infections, despite intermittent, clean
bladder catheterization, may further complicate an

already suboptimal scenario, with development of stones.
Staghorn calculus disease (infection stones) may result
from urease-producing organisms. Nephrologists who
inherit spina biﬁda patients from pediatric urologists
and nephrologists must rapidly learn the “tricks of the
trade” when caring for these fragile patients. Treatment
may include the application of anticholinergic medications, bladder catheterization, and prophylactic antibiotic
administration. Urodynamic studies with which the
nephrologist is generally unfamiliar may be required to
guide therapy. One must also appreciate the dissociation
between serum creatinine-based methods for determining
kidney function. Low muscle mass in the lower extremities of spina biﬁda patients renders an overestimation
of function. A cystatin C-based glomerular ﬁltration rate
is recommended.
Of course, the ultimate reduction of nephron number
takes place when there is a congenitally absent kidney.
The outcome of the solitary kidney is based on multiple
factors, but obesity may be its most formidable stressor
today. However, the determining factor for glomerulosclerosis in the single kidney of obese individuals may rest
with the net elevation in single nephron glomerular ﬁltration rate,3 which is a function of total nephron number.4 A
reduction in total nephron number is correlated with an
infant’s “smallness” (ie, intrauterine growth retardation)
for gestational age and African American ethnicity.5
Fortunately, those born with 1 good kidney or those
who donate one during kidney transplantation do well,
even overweight.6 Although most cases of CAKUT occur
sporadically, in recent years, mutations in genes involved
in kidney development have been associated with variable CAKUT phenotypes in humans.7,8 One example is
kidney agenesis with hydroureter, which has been
ascribed to Islet1 deletion.9 Interestingly, the gene product
of Islet1, Isl1, is a mammalian transcription factor important in limb and heart development. Its conditional deletion in a murine model produces kidney hypoplasia/
aplasia and hydroureter. Ectopic branching of ureteric
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buds (limbs) led to ureterovesical obstruction, with consequent ureteral dilation. Apparently, the lack of Isl1 impairs bone morphogenetic protein-4 expression, the lack
of which produces a CAKUT-like phenotype. Despite
the identiﬁcation of this and other genetic disorders, the
etiopathogenesis of the vast majority of CAKUT remains
unidentiﬁed.
Vigilance for worsening of CKD in patients with acquired obstructive syndromes is another area of opportunity where urologists can interact proactively with
nephrologists. Obstruction may be insidious and silent,
yet few patients are enrolled into screening programs.
Bladder and/or ureteral pressure symptoms are unreliable
barometers of the degree of kidney dysfunction, and
objective measurements of kidney function are indispensable to the prevention of progression of CKD through
tubular atrophy and tubulointerstitial inﬂammation and
ﬁbrosis from myoﬁbroblastic production of extracellular
matrix.10 Biomarkers superior in performance to the
serum creatinine and that portend trouble would be
welcome, and there are some candidates in children. In
children with posterior urethral valve-mediated obstructive uropathy, a case-control study identiﬁed several potential biomarkers. Cases displayed greater proteinuria,
by urine protein-to-creatinine ratio, than controls by
nearly 7-fold. Aquaporin-2 excretion was remarkably
less in cases than controls and corresponds to the nephrogenic diabetes insipidus state of chronic obstruction. Urinary L1 cell adhesion molecule and transforming growth
factor-b were greatly enhanced and correlated negatively
with glomerular ﬁltration as did proteinuria.
There must be education among nephrologists and urologists that antagonism of the renin-angiotensin system
(RAS), which suppresses angiotensin II-mediated induction of transforming growth factor-b, is not contraindicated during stabilized obstructive uropathy. In fact, this
treatment may retard an invariable progression to CKD
in some individuals. To date, RAS blockade in the obstructive stages of kidney disease of children cannot be claimed
superior to that of non-RAS blockade (see article by R.
Chevalier in this issue).
Insofar as CKD patients with potential obstructive uropathy are concerned, especially elderly, African American
men at risk for prostatic hyperplasia, RAS inhibition
should be attempted. Not all patients will develop hyperkalemic kidney tubular acidosis. In fact, the majority will
not develop severe hypobicarbonatemia and/or hyperkalemia. In the event that either occurs, a loop diuretic
and/or bicarbonate therapy is warranted and permits
continuation of RAS inhibition. A loop agent is the drug
of choice in this circumstance, reversing acidosis by virtue
of its chloruretic property.
Speaking of metabolic acidosis in the context of Urology
should certainly excite any nephrologist. Reconstructive
surgery, whereby a bowel segment is removed and used
as a pseudo-bladder, is termed “augmentation cystoplasty.” The procedure augments the bladder capacity of
children and adults with inadequate bladder capacity,
detrusor muscle compliance, or exstrophy-epispadias
complex.11 The ﬁrst 2 problems may induce high
pressure-related kidney damage. This procedure is

increasingly used and has been performed for decades,
and the original indication was the contracted bladder resulting from tuberculous cystitis. Today, neuropathic
causes of diverse etiology are the reasons why patients undergo this procedure, which must be stringently followed
by a rigorous campaign of clean, intermittent catheterization.12 Cystoplasty may result in hyperchloremic metabolic acidosis, sometimes severe, and this complication
is reminiscent of that which occurs with an ileal loop or
ureterosigmoidostomy.13 The pathogenesis of acidosis results from cation and bicarbonate loss with reciprocal gain
of ammonium chloride. The clever use of a “gastric patch”
may attenuate the degree of metabolic acidosis by
secreting hydrochloric acid into the ﬁnal urine and, hopefully, the slope of decline of kidney function.14
Nephrolithiasis, which affects 5% of the population and
with a lifetime risk of nearly 10%,15 remains a testable area
within Nephrology training, and trainees are expected to
gain competency in this diverse group of disorders within
the 2 years of the standard training rubric. Yet few
Nephrology trainees have witnessed any of the 3 principal, mechanical stone removal mechanisms: extracorporeal lithotripsy, mechanical extraction, or percutaneous
nephrolithotomy. In addition, fellowship-based curriculum hours featuring kidney stones are generally few and
far between. This reality appears odd when kidney stones
are becoming more frequent and prevalent in the United
States, year over year. Nephrologists must be able to treat
and prevent stones, and this means that the access to
Nephrology clinic must be nearly on-demand and target
preventive strategies. Kidney stone clinics run by nephrologists exist but selectively, and this phenomenon may be
attributed to an economic reality: procedures pay the bills.
An opportunity exists here: collaborative clinics with
Urology-backed nephrologists.
Signiﬁcant cost savings could accrue with improved
follow-up for kidney lithiasis. In 1984, the economic
impact of stones in white male adults, aged 18 to 60 years,
was gauged at $315 million. This conservative estimate
included hospital (surgeries and room rates) and work
force costs (lost work days). In 2000, total medical expenditures for stone disease were estimated at $2.1 billion.16
Certainly, disease recurrence and the net cost of care
may be reduced through collaboration between urologists
and nephrologists. Overlaying of a sophisticated Markov
model over a decision analytic model to determine costeffectiveness of increasing ﬂuid volume intake to more
than 2 L daily provided eye-opening conclusions. Simply
imbibing more water could reduce nephrolithiasis costs
by as much as 25% in the nationalized, French health
care system.17 Another cost-saving measure rarely initiated by nephrologists is medical expulsive therapy.
Medical expulsive therapy of distal ureteral stones by
a1-blockade may be initiated by internists and nephrologists and reduce hospitalizations and expensive imaging
studies18—something the patients are clamoring for as
exempliﬁed in a recent story in the Time magazine.19
Hopefully, after completing this issue of Advances in
Chronic Kidney Disease, the reader will more fully appreciate
how urological disorders intersect with Nephrology. In set
theory, when the elements of 2 different sets have like
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Figure 1. Nephrology X Urology. The separate disciplines of
Nephrology and Urology are represented as intersecting
sets. The elements resulting from the intersection represent
disorders that the nephrologist may encounter in clinical
practice. CAKUT, congenital anomalies of the kidney and urinary tract; VUR, vesicoureteral reflux.
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members, an intersection is born but possibly less clearly
delineated than by a well-ordered, 2-set Venn diagram in
which all elements are absolutely deﬁned (Fig 1). Nonetheless, it is imperative that nephrologists engage urological
intersections with high enthusiasm and seek to expand
their volume within an enriched, collaborative care model
based on a shared, foundational knowledge and abiding interest in delivering high-quality, cost-effective care.
We live immersed in narrative, recounting and reassessing the meaning of our past actions, anticipating
the outcome of our future projects, situating ourselves at the intersection of several stories not yet
completed.—P.B.
Jerry Yee, MD
Editor-in-Chief
Detroit, MI
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